GlassScriptPhysician profile
Vijay Krishna Prabhakar
NPI 1932593167
$3,569.52
in general payments reported to CMS, 2019-2025
22 companies · $1,920 in 2025
The $1,920 reported for 2025 was more than what 78% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $374 · 2023: $214 · 2024: $1,061 · 2025: $1,920.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,195.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $406.04 | 2022-2025 | Entyvio, Eohilia |
| Genzyme Corporation | $393.96 | 2023-2025 | |
| Janssen Biotech, INC. | $361.77 | 2024-2025 | Tremfya, Stelara, Simponi Aria |
| Ardelyx, INC. | $316.04 | 2023-2025 | Ibsrela |
| Abbvie INC. | $249.99 | 2022-2025 | |
| Lilly USA, LLC | $240.76 | 2024-2025 | Omvoh |
| Pfizer INC. | $240.62 | 2023-2025 | |
| Histosonics, INC. | $228.20 | 2025 | |
| Madrigal Pharmaceuticals | $197.18 | 2024-2025 | Rezdiffra, Resmetirom |
| Enterra Medical, INC. | $165.76 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $156.71 | 2025 | Iqirvo |
| Intercept Pharmaceuticals, INC. | $135.72 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $122.46 | 2023 | Zeposia |
| Celltrion USA INC. | $113.02 | 2025 | Zymfentra |
| Fresenius Kabi USA, LLC | $64.43 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Albireo Pharma, INC. | $49.58 | 2024 | Iqirvo, Bylvay |
| Qol Medical, LLC | $29.65 | 2024 | Sucraid |
| Azurity Pharmaceuticals, INC. | $25.81 | 2025 | Suflave |
| Conmed Corporation | $24.48 | 2025 | Conmed Biliary |
| Gilead Sciences, INC. | $22.25 | 2025 | |
| Phathom Pharmaceuticals, INC. | $13.42 | 2025 | Voquezna |
| Boston Scientific Corporation | $11.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vijay Prabhakar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.